Substituted benzoic acid derivatives exhibiting NF-κB inhibiting activity

专利摘要:
The present invention relates to substituted benzoic acid derivatives of formula (I) which have an NF-κB inhibitory action. Formula I In Formula I, R 1 is a group of Formula II or Formula III, R 2 is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, X is a carboxyl group which may be esterified or amidated. Formula II Formula III In Chemical Formulas II and III, R 3 , R 4 and R 5 are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms, R 9 and R 10 are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an acyl group having 2 to 11 carbon atoms.
公开号:KR20040034573A
申请号:KR10-2003-7006703
申请日:2002-09-11
公开日:2004-04-28
发明作者:스즈키겐지；누노카와요이치
申请人:다이이찌 산토리 파마 가부시키가이샤；가부시키가이샤 다이이찌 산토리 세이부쓰 이가쿠 겐큐쇼；
IPC主号:

专利说明:

Substituted benzoic acid derivatives exhibiting NF-κB inhibitoring activity
[2] NF-κB is one of the so-called transcriptional regulators of proteins that performs the regulation of gene expression. When normal cells are stimulated with inflammatory cytokines such as interleukin-1 (IL-1) or TNF-α, lipopolysaccharide, or ultraviolet light, NF-κB is activated and migrates from the cytoplasm to the nucleus, and the specific sequence on genomic DNA To be involved in the expression of various genes (see Blackwell, TS). and Christman, J.W. (1997) Am. J. Respir. Cell. Mol. Biol., 17, 3-9].
[3] Genes under expression control by NF-κB include inflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α, and cell adhesion molecules such as ICAM-1, VCAM-1, and ELAM-1. Much has been shown to be involved in immune inflammatory responses, such as induced NO synthase (iN0S). Collins, T., Read, MA, Neish, AS, Whitley, MZ, Thanos, D. and Maniatis, T. (1995) Faseb. J., 9, 899-909. In addition, it is known that inflammatory cytokines transmit signals activating NF-κB along various pathways when they bind to the receptor, and this is thought to be a cause of further exacerbation of inflammation. As such, activation of NF-κB in inflammation is understood as a cause and exacerbation factor of disease. Baeuerle, P.A. and Baichwal, V.R. (1997) Adv. Immunol. 65, 111-137.
[4] In addition, HIV, HTLV-1, CMV, adenovirus and the like have recently been reported to activate NF-κB in host cells [Dezube, BJ, Pardee, AB, Beckett, LA, Ahlers, CM, Ecto, L]. Allen-Ryan, J., Anisowicz, ZA, Sager, R. and Crumpacker, CS. (1992) J. Acquir. Immune Defic. Syndr., 5, 1099-1104; Nabel, G. and Baltimore, D. (1987) Nature 326, 711-713; Fazely, F., Dezube, B.J., Allen-Ryan, J., Pardee, A.B. and Ruprecht, R.M. (1991) Blood, 77, 1653-1656; Munoz, E. and Israel, A. (1995) Immunobiology, 193, 128-136], it is believed that activation of NF-κB is involved in the self-replicating and propagation of virus in infected host cells.
[5] Accordingly, by inhibiting the activation of NF-κB, it is possible to suppress and induce the expression of their inflammatory cytokines, cell adhesion molecule genes and viruses, and NF-κB activation inhibitors are directly or indirectly activated by NF-κB. It is promising as a therapeutic agent, immunosuppressant or viral disease treatment for diseases causing, in particular various inflammatory diseases and autoimmune diseases.
[6] Currently, many anti-inflammatory agents are used clinically for the treatment of deformed arthrosis, low back pain, chronic rheumatoid arthritis, etc., but there is no effective yet to suppress the production of various inflammatory cytokines and expression of cell adhesion molecules. It is not. Frequently used NSAIDs (nonsteroidal anti-inflammatory agents) inhibit the production of prostaglandins by inhibiting cyclooxygenase in the arachidonic acid metabolic pathway, but generally do not inhibit the production of direct cytokines. Steroids inhibit the production of many cytokines, but are known to cause toxic side effects such as undesired hormonal action, worsening of infectious diseases, the development of peptic ulcers, central action, and the like.
[7] However, recently, among these anti-inflammatory agents, some drugs that inhibit the activation of NF-κB at high doses have been reported [Auphan, N., DiDonato, JA, Rosette, C., Helmberg, A. and Karin, M. (1995). ) Science 270, 286-290 .; Shackelford, R.E., Alford, P.B., Xue, Y., Thai, S.F., Adams, D.0. and Pizzo, S. (1997) Mol. Pharmacol., 52, 421-429 .; Bitko, V., Velazquez, A., Yang, L., Yang, Y.C. and Barik, S. (1997) Virology, 232, 369-378. For example, benzoic acid derivatives such as salicylic acid and aspirin have been reported to inhibit the activation of NF-κB (see Science, 265, 956-959, 1994). Expression is pointed out as a problem.
[8] Therefore, the development of a highly stable drug that specifically inhibits the activation of NF-κB is desired, and many researchers have been searching for a molecule and designing an NF-B activation inhibitor.
[9] Recently, isocarbazole derivatives [JP-A-8-319238, 2000-169479] and isoquinoline derivatives [JP-A-10-] as an inhibitor of NF-κB activation. 87491, Japanese Patent Application Laid-Open No. 11-180873], benzoquinone derivatives [Japanese Patent Application Laid-Open No. Hei 7-291859, Japanese Patent Application No. 11-266872], and β-lactam derivatives. 11-71278], lignan derivatives [JP-A-10-175861], benzylidene derivatives (PCT / JP 98/04774), pyrimidine-5-carboxamide derivatives (WO agent) 97/09315, WO 97/09325), cyclopentabenzofuran derivatives (WO 00/08007), benzene derivatives (WO 00/15603), pyrrolidinedithiocarbonates (PDTC) [Eur. J. Immunol. (1999) 29, 1890-1900), 3-deazaadenosine (DZA) [J. Biol. Chem. (1999) 274, 27, 18981-18988], 2,2'-bi-1H-pyrrole derivatives [J. Immunol. (1999) 162, 7102-7109, and the like.
[10] Although many of these substances are unclear about the mechanism of action of inhibiting the activation of NF-κB, the substance that is considered to be caused by antioxidant activity or the inhibition of phosphorylation of proteins is considered to be a problem in terms of stability and specificity of action. do. At present, no drug having a sufficient effect as an activation inhibitor of the transcription factor NF-κB has been obtained.
[11] As an example in which a substituted benzoic acid derivative acts on a transcriptional regulator or a transcription factor receptor, for example, a retinoic acid derivative, which is a substituted benzoic acid derivative, is applied to a transcription factor receptor such as a retinoic acid receptor (RAR) or a retinoic acid X receptor (RXR). It has been reported to exhibit agonist action or antagonist action (see Kagechika H., Kawachi E., Hashimoto Y., Himi T., Shudo K., J. Med. Chem., 1989, 31, 2182). Boehm.MF, Zhang L., Badea BA, White SK, Mais DE, Suto CM, Goldman ME, Heyman RA, J. Med. Chem., 1994, 37, 2930 .: Boehm.MF, Zhang L., Zhi L., McClurg MR, Berger E., Wagoner M., Mais DE, Suto CM, Davis PJA, Heyman RA, Nadzan AM, J. Med. Chem., 1995, 38, 3146). However, no NF-κB inhibitory activity of these retinobenzoic acid derivatives has been reported.
[12] On the other hand, in JP-A-7-291859, a benzoquinone derivative of the formula (A) is disclosed as an activation inhibitory substance of NF-κB.
[13]
[14] In addition, Japanese Laid-Open Patent Publication No. Hei 11-266872 discloses a novel screening method for a substance that inhibits the activation of NF-κB, which inhibits the activation of NF-κB that can be found by the method. Examples of the substance include benzoquinone derivatives of the general formula (B).
[15]
[16] However, it is not a compound having sufficient potency as an NF-κB inhibitor, and a search for a substance with stronger NF-B inhibitory activity is desired.
[17] Disclosure of the Invention
[18] The present invention provides a prophylactic and therapeutic agent for diseases caused by the activation of NF-κB by inhibiting the activation of NF-κB, for example, the disease caused by the overproduction of various inflammatory mediators or the proliferation of viruses. More specifically, diseases in which overproduction of N0 or TNF-α is thought to be the cause of onset, such as sepsis shock, deformable arthritis, chronic joint rheumatism, cachexia, multiorgan insufficiency, inflammatory bowel disease, malaria, acquired immunodeficiency syndrome To provide the treatment and prevention of human T cell leukemia, meningitis, hepatitis, myocarditis, type II diabetes, multiple sclerosis, Behcet's disease, systemic lupus erythematosus, ischemic heart disease.
[19] The present inventors have intensively studied a substance which inhibits the activation of NF-κB, and as a result, a novel substituted benzoic acid derivative of formula (I), its hydroquinone form or a pharmacologically acceptable salt thereof is strongly resistant to NF-κB. It was found that the activation was inhibited and the present invention was completed.
[20] That is, the present invention provides a novel NF-κB inhibitor comprising a substituted benzoic acid derivative of formula (I), the new substituted benzoic acid derivative, a hydroquinone form thereof, or a pharmacologically acceptable salt thereof as an active ingredient and inflammatory diseases thereof , As an agent for the prophylaxis or treatment of autoimmune diseases, viral diseases, which include IL-1, TNF-α, IL-2, IL-6, IL-8, iN0S, granulocyte colony stimulating factor, interferon-γ, ICAM-1, VCAM-1, ELAM-1, major histocompatibility class I, major histocompatibility class II, β-2 microglobulin, immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B, It is used as an inhibitor of expression of genes of one or more substances selected from the group consisting of complement C4, c-myc, HIV, HTLV-1, SV-40, CMV and adenovirus.
[21]
[22] In Formula I,
[23] R ¹ is a group of Formula II or Formula III,
[24] R ² is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted,
[25] X is a carboxyl group which may be esterified or amidated.
[26]
[27]
[28] In Chemical Formulas II and III,
[29] R ³ , R ⁴ and R ⁵ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms,
[30] R ⁹ and R ¹⁰ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an acyl group having 2 to 11 carbon atoms.
[31] Also provided is a prophylactic or therapeutic agent for a disease resulting from the activation of NF-κB, comprising as an active ingredient a novel substituted benzoic acid derivative of Formula I, its hydroquinone form or a pharmacologically acceptable salt thereof.
[32] In addition, when the substituted benzoic acid derivative, which is an active ingredient of the present invention, has a benzoquinone ring in its molecule, it can be easily reduced to obtain the corresponding hydroquinone form. Accordingly, in the present invention, the hydroquinone form in which the benzoquinone ring in the molecule of the substituted benzoic acid derivative which is the active ingredient of the present invention is reduced may also be used as the active ingredient of the present invention. In the hydroquinone form, the benzoquinone derivative according to the present invention is converted into a hydroxyl group by reducing oxo at 1 and / or 4 positions of the benzoquinone ring chemically by a catalyst or the like or biochemically by an enzyme or the like, or reduced in vivo. Also means a product having the same activity as the benzoquinone derivative.
[33] In addition, as the pharmacologically acceptable salt, for example, inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid or maleic acid, fumaric acid, tartaric acid, lactic acid, citric acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, Salts of organic acids such as adipic acid, palmitic acid and tannic acid, and inorganic metals such as alkali metals such as lithium, sodium, potassium, and alkaline earth metals such as calcium and magnesium, and basic amino acids such as lysine.
[34] In the above formulae, R ¹ represents a group of the following formula (II) or (III).
[35] Formula II
[36]
[37] Formula III
[38]
[39] In the above formula, R ³ , R ⁴ and R ⁵ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms, and preferred examples of the alkyl group include methyl, ethyl, propyl, isopropyl, C1-C6 straight or branched saturated aliphatic hydrocarbon groups such as n-butyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, tertiary pentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclo Saturated alicyclic hydrocarbon groups, such as pentyl and cyclohexyl, and saturated alicyclic hydrocarbon groups-aliphatic hydrocarbon groups, such as cyclopropylmethyl, cyclopropylethyl, and cyclobutylmethyl, etc. are mentioned. In addition, an alkoxy group means the group by which the said alkyl group was couple | bonded with the oxygen atom, As a preferable example of an alkoxy group, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, secondary butoxy, tertiary C1-C6 linear or branched alkoxy groups, such as butoxy, are mentioned.
[40] R ⁹ and R ¹⁰ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an acyl group having 2 to 11 carbon atoms, and preferred examples of the alkyl group include methyl, ethyl, propyl, isopropyl, n-butyl, and secondary C1-C6 straight or branched saturated aliphatic hydrocarbon groups such as butyl, tertiary butyl, pentyl, isopentyl, neopentyl, tertiary pentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. Saturated alicyclic hydrocarbon group, and saturated alicyclic hydrocarbon group-aliphatic hydrocarbon group, such as cyclopropylmethyl, cyclopropylethyl, and cyclobutylmethyl, etc. are mentioned. In addition, preferred examples of the acyl group include acetyl, propanoyl, butanoyl, cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, 2-pyridinecarbonyl, 3-pyridinecarbonyl, and 4-pyridinecarbonyl. And groups such as neil.
[41] R ² is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, and an aryl group having 6 to 12 carbon atoms which may be substituted or a heteroaryl group having 4 to 11 carbon atoms which may be substituted is preferable.
[42] Preferred examples of the aryl group having 6 to 12 carbon atoms that may be substituted include phenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3,4-dimethoxyphenyl, 4-chlorophenyl, 3- Chlorophenyl, 2-chlorophenyl, 4-nitrophenyl, 4-cyanophenyl, 4-trifluoromethylphenyl, 2,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3,4-dichloro And groups such as phenyl, 4-morpholinylphenyl and 1-naphthyl.
[43] Further, preferred examples of the heteroaryl group having 4 to 11 carbon atoms that may be substituted include 4-pyridyl, 3-pyridyl, 2-pyridyl, 2-furanyl, 3-furanyl, 2-pyrimidyl, 4- And groups such as pyrimidyl, 2-quinolyl and 3-isoquinolyl.
[44] Specific examples of the substituent of "substituted" in the present invention include, for example, alkyl, alkoxy, aryl, heteroaryl, hydroxy, acyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl, carbamoyl which may be substituted, Substituents, such as amino and cyano which may be substituted, and a halogen atom etc. are mentioned.
[45] X is a carboxyl group which may be esterified or amidated, and as a preferred example of a carboxyl group which may be esterified or amidated, a group of the formula -COOR ⁶ , wherein R ⁶ is a hydrogen atom, which may be substituted with 1 to C A lower alkyl group of 6 or an optionally substituted aralkyl group having 7 to 14 carbon atoms, a group of the formula -C0NR ⁷ R ⁸ , wherein R ⁷ and R ⁸ are each independently a hydrogen atom, which may be substituted with 1 to 6 carbon atoms Lower alkyl groups, optionally substituted aryl groups having 6 to 12 carbon atoms, optionally substituted heteroaryl groups having 4 to 11 carbon atoms, optionally substituted aralkyl groups having 7 to 14 carbon atoms, and substituted groups having 5 to 13 carbon atoms or heteroarylalkyl group, R ⁷ and R ⁸ may further contain a nitrogen atom, an oxygen atom or a sulfur atom together with the nitrogen atom to which they are bonded, or also heterocyclic ring which may be condensed The formation), and groups of formula -CONR ⁷ R ⁸ (wherein, R ⁷ and R ⁸ are selected from together with the nitrogen atom to which they are bonded, a carbon atom and a nitrogen atom in addition to nitrogen atom, oxygen atom and sulfur atom which may be substituted with 1 To form a 5-8 membered nitrogen-containing heterocyclic ring which may contain from 3 to 3 heteroatoms, wherein carbon or sulfur atoms on the ring may be present in oxide form).
[46] Preferred examples of lower alkyl groups having 1 to 6 carbon atoms which may be substituted are, for example, methyl, ethyl, tertiary butyl, hydroxyethyl, alkoxyethyl, aminoethyl, mono or disubstituted aminoethyl (e.g., N-methylamino And ethyl, N, N-dimethylaminoethyl), cyanomethyl, carboxymethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl and carbamoylmethyl.
[47] Preferred examples of the aralkyl group having 7 to 14 carbon atoms which may be substituted include benzyl, 4-nitrobenzyl, 3-nitrobenzyl, 4-methoxybenzyl, 3-methoxybenzyl, 4-chlorobenzyl, 2-phenethyl, 3 Groups, such as -phenylpropyl, are mentioned.
[48] Preferred examples of the aryl group having 6 to 12 carbon atoms that may be substituted include phenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4,5-tri And groups such as methoxyphenyl, 4-trifluoromethylphenyl, 4-morpholinophenyl, 4-cyanophenyl, 4-chlorophenyl, 4-nitrophenyl, 1-naphthyl and the like.
[49] Preferred examples of the heteroaryl group having 4 to 11 carbon atoms that may be substituted include 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 2-thienyl, 2-pyrimidinyl, 2-qui And groups such as nilyl and 3-isoquinolyl.
[50] Preferred examples of a substituted heteroarylalkyl group having 5 to 13 carbon atoms include 4-pyridylmethyl, 3-pyridylmethyl, 2-pyridylmethyl, 2- (pyridin-4-yl) ethyl, and 2- (pyridine- And groups such as 3-yl) ethyl, 2-quinolylmethyl, and 3-isoquinolylmethyl.
[51] A halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
[52] Moreover, as a preferable compound in this invention, the compound of the following general formula (I) is mentioned.
[53] Formula I
[54]
[55] In Formula I,
[56] R ¹ is a group of formula (II)
[57] R ² is a phenyl group, 4-methoxyphenyl group, 3-methoxyphenyl group, 2-methoxyphenyl group, 3,4-dimethoxyphenyl group, 4-pyridyl group, 3-pyridyl group, 2-pyridyl group, 2-furanyl group Or 3-furanyl group,
[58] X is a carboxyl group which may be esterified or amidated.
[59] Formula II
[60]
[61] In Chemical Formula II,
[62] R ³ and R ⁴ are a methyl group or a methoxy group,
[63] R ⁵ is a methyl group.
[64] Particularly preferred specific compounds include the following compounds.
[65] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid methyl ester,
[66] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester,
[67] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid methyl ester,
[68] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-methoxyphenyl) benzoic acid methyl ester,
[69] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-methoxyphenyl) benzoic acid methyl ester,
[70] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (2-methoxyphenyl) benzoic acid methyl ester,
[71] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester,
[72] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid methyl ester,
[73] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester,
[74] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid methyl ester,
[75] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid,
[76] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid,
[77] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid,
[78] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-methoxyphenyl) benzoic acid,
[79] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-methoxyphenyl) benzoic acid,
[80] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (2-methoxyphenyl) benzoic acid,
[81] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid,
[82] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid,
[83] N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine,
[84] N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] morpholine,
[85] N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline,
[86] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid,
[87] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid,
[88] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] piperidine,
[89] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] morpholine,
[90] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline,
[91] N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine,
[92] (S) -N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -1-phenylethylamine,
[93] N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] piperidine,
[94] (S) -N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -1-phenylethylamine,
[95] N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline,
[96] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine,
[97] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] morpholine,
[98] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline,
[99] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoic acid,
[100] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid,
[101] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid,
[102] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoic acid,
[103] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoic acid,
[104] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (2-methoxyphenyl) benzoic acid,
[105] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] piperidine,
[106] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] morpholine,
[107] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] -4-trifluoromethylaniline,
[108] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] piperidine,
[109] 4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid,
[110] 4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid,
[111] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] piperidine (methanesulfonate),
[112] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] morpholine,
[113] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -4-methoxyaniline (hydrochloride),
[114] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline,
[115] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoyl] piperidine,
[116] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoyl] morpholine,
[117] (S) -N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-phenylethylamine (Methanesulfonate),
[118] (R) -N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-phenylethylamine (Methanesulfonate),
[119] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] cyclohexylamine (methanesulfonate),
[120] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] cyclopentylamine (methanesulfonate),
[121] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] cyclopropylamine (methanesulfonate),
[122] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-ethylpropylamine (methanesulfonate ),
[123] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] piperidine,
[124] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] morpholine,
[125] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-methoxyaniline,
[126] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline,
[127] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] -4-methoxyaniline,
[128] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoyl] -4-methoxyaniline,
[129] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoyl] piperidine,
[130] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoyl] morpholine,
[131] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoyl] -4-methoxyaniline,
[132] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (2-methoxyphenyl) benzoyl] -4-methoxyaniline,
[133] N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] piperidine,
[134] (S) -N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -1-phenylethylamine ,
[135] N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] piperidine,
[136] (S) -N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-phenylethylamine ,
[137] N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline,
[138] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] morpholine,
[139] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline,
[140] N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-methoxyaniline,
[141] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] piperidine,
[142] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] morpholine and
[143] N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] -4-trifluoromethylaniline.
[144] Next, the example of the manufacturing method of a compound for implementing this invention is demonstrated. However, the manufacturing method of the compound which is an active ingredient of this invention is not limited to these.
[145] [General manufacturing method]
[146] Substituted benzoic acid derivatives of formula (I) used as active ingredients of the present invention are known per se methods, i.e. the paper (Suzuki, K., Tatsuoka, T., Ishihara, T., Ogino, R., Miyazaki, T ., Satoh, F., Miyano, S., Sumoto, K., Chem. Pharm. Bull., (1997) 45, 668-674) and synthetic intermediates that can be prepared according to the methods according to them. Can be prepared.
[147] Specifically, the aldehyde compound of formula (IV) is reacted with a Grignard reagent or an organolithium reagent prepared from a halogenated phenol derivative to give a compound of formula (V), which is converted to Lewis acid or trimethylsilyltrifluoromethanesulfonate ( It is reduced with a reducing agent such as triethylsilane in the presence of a catalyst such as TMSOTf) and then stirred under a hydrogen atmosphere in the presence of a catalyst such as palladium-carbon to reduce the contact to obtain a phenol derivative of formula VI.
[148]
[149]
[150]
[151] In Formulas IV to VI,
[152] R ³ to R ⁵ , R ⁹ and R ¹⁰ are the same as defined above.
[153] The compound is stirred with hexamethylenetetramine at room temperature to 100 ° C. in a solvent such as trifluoroacetic acid, and then hydrolyzed to obtain a compound of formula VIIa.
[154]
[155] In Formula VIIa,
[156] R ³ to R ⁵ , R ⁹ and R ¹⁰ are the same as defined above.
[157] The compound is then stirred at a temperature of 0 ° C. to reflux temperature, preferably room temperature to 50 ° C., with an alkylating agent such as benzyl bromide in the presence of a base such as potassium carbonate or sodium hydroxide in a solvent not involved in the reaction of acetone or the like. Thus, a compound of formula VIIb is obtained.
[158]
[159] In Formula VIIb,
[160] R ³ to R ⁵ , R ⁹ , R ¹⁰ and Bn are the same as defined above.
[161] For example, the compound is dissolved in a solvent that does not participate in the reaction, such as acetonitrile, and stirred at a temperature of 0 to 50 ° C. in the presence of an oxidizing agent such as sodium hypochlorite and hydrogen peroxide in a mixed solution with a phosphate buffer solution. A substituted benzoic acid derivative of formula VIII is obtained.
[162]
[163] In Formula VIII,
[164] R ³ to R ⁵ , R ⁹ , R ¹⁰ and Bn are the same as defined above.
[165] Next, such a carboxylic acid compound is treated with diazomethane, trimethylsilyldiazomethane or the like in a solvent not involved in the reaction such as methanol, or 4-dimethylaminopyridine or the like in a solvent not involved in the reaction such as methylene chloride. In the presence or absence of a catalyst, a dehydrating condensing agent such as, for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC-HCl), or acid with oxalyl chloride or the like Condensed with alcohols of formula (IX) in the form of a chloride, and then stirred at room temperature to 50 ° C. under a hydrogen atmosphere in the presence of a catalyst such as palladium-carbon in a solvent not involved in the reaction of ethanol, 1,4-dioxane or the like. By catalytic reduction, compounds of formula (Xa) can be obtained.
[166] R ⁶ -OH
[167]
[168] In Formulas IX and Xa,
[169] R ⁶ is a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 14 carbon atoms,
[170] R ³ to R ⁵ , R ⁹ and R ¹⁰ are the same as defined above,
[171] X 'is an esterified carboxyl group.
[172] The compound of formula (Xa) is reacted with trifluoromethanesulfonyl chloride or trifluoromethanesulfonic anhydride in the presence of a base such as triethylamine in a solvent that is not involved in the reaction such as methylene chloride, Compounds can be obtained.
[173]
[174] In Chemical Formula Xb,
[175] R ³ to R ⁵ , R ⁹ , R ¹⁰ and X 'are the same as defined above.
[176] The compound of formula (Xb) is a reagent such as lithium chloride, sodium carbonate, sodium dihydrogen phosphate in a solvent that does not participate in the reaction of toluene, acetonitrile, 1,4-dioxane, dimethylformamide, water or the like or a mixed solvent thereof. In the presence of a catalyst such as tetrakis (triphenylphosphine) palladium in the presence of a condensation with a boronic acid derivative of formula (XI) or an organic tin reagent of formula (XII) to obtain a compound of formula (Ia) Can be.
[177]
[178] R ² -Sn (n-Bu) ₃
[179]
[180] In Formulas Ia, XI and XII,
[181] R ² is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted,
[182] R ³ to R ⁵ , R ⁹ , R ¹⁰ and X 'are the same as defined above.
[183] The compound can be stirred and hydrolyzed in the presence of a base such as sodium hydroxide, for example in a mixed solvent of dioxane and water, to give a substituted benzoic acid derivative of formula (Ib).
[184]
[185] In Chemical Formula Ib,
[186] R ² , R ³ to R ⁵ , R ⁹ and R ¹⁰ are the same as defined above.
[187] The compound is again treated with diazomethane, trimethylsilyldiazomethane, etc. in a solvent not involved in the reaction such as methanol, or a catalyst such as 4-dimethylaminopyridine in a solvent not involved in the reaction such as methylene chloride. In the presence or absence, for example, by using a dehydrating condensing agent such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, condensation with alcohols of formula XIII or amines of formula XIV, Obtain the compound.
[188] R ⁶ -OH
[189]
[190]
[191] In Chemical Formulas XIII, XIV, and Ic,
[192] R ⁶ is a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 14 carbon atoms,
[193] R ⁷ and R ⁸ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms which may be substituted, an aryl group having 6 to 12 carbon atoms which may be substituted, a heteroaryl group having 4 to 11 carbon atoms which may be substituted, Or an aralkyl group having 7 to 14 carbon atoms or a heteroarylalkyl group having 5 to 13 carbon atoms which may be substituted, or R ⁷ and R ⁸ may further contain a nitrogen atom, an oxygen atom, and a sulfur atom together with the nitrogen atom to which they are attached; To form a heterocyclic group which may be condensed,
[194] R ² , R ³ to R ⁵ , R ⁹ and R ¹⁰ are the same as defined above,
[195] X ″ is an esterified or amidated carboxyl group.
[196] Compounds of formulas (Ia), (Ib) and (Ic) may be oxidized with an oxidizing agent such as dicerium ammonium nitrate (CAN) in a solvent that does not participate in a reaction such as a mixed solvent of acetonitrile and water to obtain a benzoquinone derivative of formula (Id).
[197]
[198] In Chemical Formula Id,
[199] R ² , R ³ to R ⁵ and X are as defined above.
[200] Since the substance according to the present invention, which is a compound of formula (I), can inhibit the activation of NF-κB, it is effective for diseases caused by the activation of NF-κB, for example, due to the overproduction of various inflammatory mediators or the proliferation of viruses. The usefulness as a prophylactic and therapeutic agent can be expected. Specifically, for example, diseases in which overproduction of NO or TNF-α is thought to be the cause, sepsis shock, deformable arthritis, chronic joint rheumatism, cachexia, multiorgan insufficiency, inflammatory bowel disease, malaria, acquired immunodeficiency syndrome, It is useful as a therapeutic and preventive agent for human T cell leukemia, meningitis, hepatitis, myocarditis, type II diabetes, multiple sclerosis, Behcet's disease, systemic lupus erythematosus, ischemic heart disease, and the like.
[201] When the compound according to the present invention is used as the pharmaceutical composition described above, for example, orally or in water or other pharmaceutically acceptable liquid in the form of tablets, capsules, elixirs, microcapsules, etc. It can be used parenterally in the form of an injection such as a solution or suspension. For example, it may be prepared by mixing the compound with a physiologically acceptable carrier, flavoring agent, excipient, stabilizer and the like in a generally accepted form. As an additive that can be mixed into tablets, for example, a binder such as gelatin, a swelling agent such as corn starch, an excipient such as crystalline cellulose, a lubricant such as magnesium stearate, and the like can be used. In the case of capsule formulations, the composition may further contain a liquid carrier. Sterile compositions for injection may also be applied to conventional formulations.
[202] Examples of the aqueous solution of the injection include an isotonic solution containing glucose and the like, and can be used in combination with a suitable dissolution aid such as polyethylene glycol. In addition, buffers, stabilizers, preservatives, antioxidants, analgesics, and the like can be blended. The agent thus obtained can be administered to mammals including humans, for example. Dosage varies depending on symptoms and the like, but for oral administration, it is generally about 0.01 to 500 mg, preferably about 0.1 to 50 mg, more preferably about 1.0 to 25 mg per day for adults. In the case of parenteral administration, for example, in the case of injection, in general, about 0.001 to 50 mg per day, preferably about 0.01 to 25 mg, more preferably about 0.1 to 10 mg per day to adults is administered by intravenous injection It is desirable to.
[203] NF-κB inhibitory effects can be investigated by directly or indirectly measuring the expression of genes that are controlled by the activation of NF-κB.
[204] In addition, the effect of inhibiting overexpression of inflammatory proteins is to stimulate the cell or animal solid with cytokines such as IL-1, TNF-α, lipopolysaccharide, or the like, thereby directly or indirectly increasing the amount of inflammatory proteins in culture or body fluids. It can investigate by measuring. Moreover, as a method of confirming broad anti-inflammatory effect, it can investigate by the effect which suppresses the edema caused by carrageenin, dextran, etc.
[205] In these models, it has been shown to be effective to inhibit the production of NO or TNF-α. Filion, M.C. and Phillips, N.C. (1997) Br. J. Pharmacol., 122, 551-557 .; Tsao, P.W., Suzuki, T., Totsuka, R., Murata, T., Takagi, T., Ohmachi, Y., Fujiwara, H., and Takata, I. (1997) Clin. Immunol. Immunopathol. (1997) 83, 173-178 .; Cuzzocrea, S., Zmgarelli, B., Hake, P., Salzman, A.L. and Szabo, C. Free Radic. Biol. Med. (1998) 24, 450-459.
[206] In addition, with respect to specific diseases, the effect as a sepsis therapeutic agent can be judged by administering lipopolysaccharide to animals, such as a mouse, and improving the survival rate, or by measuring the amount of inflammatory cytokines in blood. The effect as a therapeutic agent for chronic articular rheumatoid can assess the efficacy in model animals of arthritis caused by adjuvant or collagen (Y. Iigo et al., J. Immunol., (1991) 147, 4167).
[207] In addition, the effect as a therapeutic agent for intractable inflammation, for example, clone's disease, hepatitis, nephritis, can be estimated in the animal model constructed according to a method known per se or according to the method [K. Nishikawa et al. al., J. Exp. Med., (1994) 180, 95; K. Kawasaki et al., J. Immunol., (1992) 150, 1074]. In addition, the effect as an organ transplant rejection inhibitor can evaluate the efficacy in, for example, graft versus host (GVH) disease or various organ transplant model animals. See A.B. Cosimi et al., J. Immunol., (1990) 142, 2617; M. Isobe et al., Science, (1992) 255, 1125].
[208] Thus, the effect of NF-κB inhibitor as a disease therapeutic agent can be confirmed by the various animal models which can be constructed by a well-known method or a method similar thereto.
[209] Next, although an Example and an experimental example are given and this invention is further demonstrated, this invention is not limited to these Examples and an experimental example.
[210] Reference Example 1:3- (benzyloxy) bromobenzene
[211] 3-bromophenol (50 g, 0.289 mol) is dissolved in acetone (500 ml), anhydrous potassium carbonate (80 g, 0.580 mmol) and benzyl bromide (59 g, 0.345 mol) are added sequentially and heated to reflux for 3 hours. The reaction mixture is filtered and the filtrate is concentrated under reduced pressure. The obtained crude reaction product is recrystallized (double recrystallization operation using hexane as a solvent) to give the title compound (45.0 g, 0.171 mol, 59%).
[212] Reference Example 2:4- (benzyloxy) bromobenzene
[213] 4-bromophenol (100 g, 0.587 mol) is dissolved in acetone (1100 ml), anhydrous potassium carbonate (159.53 g, 1.156 mmol) and benzyl bromide (103.78 g, 0.607 mol) are added sequentially and heated to reflux for 3 hours. . The reaction mixture is filtered and the filtrate is concentrated under reduced pressure. The crude reaction product obtained is recrystallized with hexane to give the title compound (120.76 g, 0.459 mol, 79%).
[214] Reference Example 3:2- (benzyloxy) bromobenzene
[215] 2-bromophenol (50.0 g, 0.289 mol) was dissolved in acetone (400 ml), anhydrous potassium carbonate (79.89 g, 0.578 mmol) and benzyl bromide (59.32 g, 0.347 mol) were added sequentially to reflux for 3 hours. Let's do it. The reaction mixture is filtered and the filtrate is concentrated under reduced pressure. The crude reaction product obtained is purified by silica gel column chromatography (hexane: Ac0Et = 95: 5) to afford the title compound (30.0 g, 0.114 mol, 40%).
[216] Reference Example 4:1- (3,4,5,6-tetramethoxy-2-methylphenyl) -1- (3-benzyloxyphenyl) methanol
[217] 3,4,5,6-tetra in Grignard reagent (150 ml tetrahydrofuran solution) prepared from 3- (benzyloxy) bromobenzene (18.4 g, 0.070 mol) and magnesium (1.87 g, 0.077 mol) under ice cooling Anhydrous tetrahydrofuran (50 ml) solution of methoxy-2-methylbenzaldehyde (14 g, 0.058 mol) is added dropwise, followed by further stirring for 2 hours. The reaction solution is poured into saturated aqueous ammonium chloride solution and ether extracted. The extract is washed with saturated brine and then dried. The reaction solution was filtered and the crude product obtained by concentrating the filtrate was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (23.5 g, 0.055 mol, 95%).
[218] Reference Example 5:1- (3,4,5,6-tetramethoxy-2-methylphenyl) -1- (4-benzyloxyphenyl) methanol
[219] 3,4,5,6-tetra in Grignard reagent (30 ml tetrahydrofuran solution) prepared from 4- (benzyloxy) bromobenzene (8.00 g, 0.030 mol) and magnesium (0.81 g, 0.033 mol) under ice cooling. Anhydrous tetrahydrofuran (20 ml) solution of methoxy-2-methylbenzaldehyde (3.65 g, 0.015 mol) is added dropwise, followed by further stirring for 2 hours. The reaction solution is poured into saturated aqueous ammonium chloride solution and ether extracted. The extract is washed with saturated brine and then dried. The reaction was filtered and the crude product obtained by concentrating the filtrate was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (5.93 g, 0.014 mol, 92%).
[220] Reference Example 6:1- (3,4,5,6-tetramethoxy-2-methylphenyl) -1- (2-benzyloxyphenyl) methanol
[221] 3,4,5,6-tetra in Grignard reagent (35 ml tetrahydrofuran solution) prepared from 2- (benzyloxy) bromobenzene (11.50 g, 0.044 mol) and magnesium (1.16 g, 0.048 mol) under ice cooling Anhydrous tetrahydrofuran (30 ml) solution of methoxy-2-methylbenzaldehyde (5.00 g, 0.021 mol) is added dropwise, followed by further stirring for 2 hours. The reaction solution is poured into saturated aqueous ammonium chloride solution and ether extracted. The extract is washed with saturated brine and then dried. The reaction was filtered and the crude product obtained by concentrating the filtrate was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (8.80 g, 0.021 mol, 99%).
[222] Reference Example 7:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) phenol
[223] To a methylene chloride solution (1000 ml) of triethylsilane (8.33 g, 71.64 mmol) and TMS0Tf (2.65 g, N.92 mmol) was added dropwise a methylene chloride solution of the compound (25.3 g, 59.67 mmol) obtained in Reference Example 4 at room temperature. Stir for 1 h. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is dissolved in ethanol (100 ml) and dioxane (150 ml) and added to an ethanol suspension (50 ml) of 5% Pd-C (3 g) and then stirred for 16 h at room temperature under a hydrogen atmosphere. The reaction solution was filtered, and the residue obtained by concentrating the filtrate was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1) to give the title compound (18.4 g, 57.9 mmol, 97%).
[224] Reference Example 8:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) phenol
[225] To the methylene chloride solution (80 ml) of triethylsilane (0.99 g, 8.52 mmol) and TMS0Tf (0.31 g, 1.39 mmol) was added dropwise a methylene chloride solution (70 ml) of the compound (3.00 g, 7.08 mmol) obtained in Reference Example 5. And stirred at room temperature for 1 hour. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is dissolved in ethanol (50 ml), added to 5% Pd-C (50 mg) ethanol suspension (250 ml) and stirred for 16 h at room temperature under hydrogen atmosphere (in this case in a mixed solvent of ethanol and dioxane) Reaction can be carried out). The reaction solution is filtered, and the residue obtained by concentrating the filtrate is purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (1.96 g, 6.15 mmol, 87%).
[226] Reference Example 9:2- (3,4,5,6-tetramethoxy-2-methylbenzyl) phenol
[227] To the methylene chloride solution (150 ml) of triethylsilane (2.95 g, 25.43 mmol) and TMS0Tf (0.94 g, 4.23 mmol) was added dropwise a methylene chloride solution (130 ml) of the compound (9.00 g, 21.23 mmol) obtained in Reference Example 6. And stirred at room temperature for 1 hour. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is dissolved in ethanol (50 ml), added to an ethanol suspension (350 ml) of 5% Pd-C (1.5 g) and then stirred for 16 hours at room temperature under a hydrogen atmosphere (in this case a mixed solvent of ethanol and dioxane) Reaction can be carried out). The reaction solution was filtered, and the residue obtained by concentrating the filtrate was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (5.67 g, 17.83 mmol, 84%).
[228] Reference Example 10:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzaldehyde (10a) and 6- (3,4,5,6-tetramethoxy-2-methylbenzyl) 2-hydroxybenzaldehyde (10b)
[229] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) phenol (11.17 g, 35.13 mmol) and hexamethylenetetramine (6.39 g, 0.046 mol) were dissolved in trifluoroacetic acid and 80 Heat stir for 4 hours at < RTI ID = 0.0 > After the reaction was completed, water was added to the residue obtained by distilling off the solvent, followed by stirring for 30 minutes, followed by extraction with methylene chloride. The extract was washed with water, dried, the solvent was distilled off and the residue obtained was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1) to give the title compound 10a (3.35 g, 9.68 mmol, 28). %) And 10b (2.03 g, 18%).
[230] Reference Example 11:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzaldehyde
[231] Dissolve 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) phenol (14.5 g, 45.60 mmol) and hexamethylenetetramine (8.30 g, 59.29 mmol) in trifluoroacetic acid (100 ml) And stirred at 80 ° C. for 4 hours. After the reaction was completed, water (10Oml) was added to the residue obtained by distilling off the solvent, followed by stirring for 30 minutes, followed by extraction with methylene chloride. The extract was washed with water, dried, the solvent was distilled off and the residue obtained was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (12.20 g, 35.26 mmol, 78%). ).
[232] Reference Example 12:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzaldehyde
[233] Dissolve 2- (3,4,5,6-tetramethoxy-2-methylbenzyl) phenol (8.64 g, 27.17 mmol) and hexamethylenetetramine (5.00 g, 35.67 mmol) in trifluoroacetic acid (100 ml) And stirred at 80 ° C. for 4 hours. After the reaction was completed, water (100 ml) was added to the residue obtained by distilling off the solvent, followed by stirring for 30 minutes, followed by extraction with methylene chloride. The extract was washed with water, dried, the solvent was distilled off and the residue obtained was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (2.50 g, 7.23 mmol, 27%). ).
[234] Reference Example 13:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzaldehyde
[235] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzaldehyde (743 mg, 2.14 mmol) was dissolved in acetone (50 ml), anhydrous sodium carbonate (593 mg, 4.30 mmol) and Benzyl bromide (477 mg, 2.79 mmol) is added and then stirred at room temperature for 16 hours. The reaction mixture was filtered, and the filtrate was concentrated to obtain a residue obtained by silica gel column chromatography (hexane: ethyl acetate = 3: 1) to give the title compound (864 mg, 1.98 mmol, 93%).
[236] Reference Example 14:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzaldehyde
[237] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzaldehyde (0.100 g, 0.290 mol) is dissolved in acetone (10 ml) and anhydrous sodium carbonate (0.080 g, 0.579 mmol) ) And benzyl bromide (0.059 g, 0.347 mmol) are added and then heated to reflux for 3 hours. The reaction solution was filtered, and the residue obtained by concentrating the filtrate was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (0.114 g, 0.261 mmol, 90%).
[238] Reference Example 15:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzaldehyde
[239] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzaldehyde (1.16 g, 3.35 mol) is dissolved in acetone (5.0 ml) and anhydrous sodium carbonate (1.02 g, 7.38) mmol) and benzyl bromide (0.69 g, 4.02 mmol) were added and then heated to reflux for 3 hours. The reaction solution is filtered, and the residue obtained by concentrating the filtrate is purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to give the title compound (1.45 g, 3.32 mmol, 99%).
[240] Reference Example 16:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid
[241] Sodium dihydrogen phosphate (157 mg, 1.31 mmol) in acetonitrile solution (5 ml) of 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzaldehyde (735 mg, 1.69 mmol) Aqueous solution (2 ml), sodium chlorite (795 mg, 80%, 7.07 mmol) aqueous solution (7 ml) and hydrogen peroxide solution (0.5 ml, 30%) were added, followed by stirring at room temperature for 16 hours. The reaction solution is diluted with water and then extracted with ethyl acetate. The extract was washed with 10% aqueous hydrosulfite (Na ₂ S ₂ O ₄ ) solution and saturated brine, dried and concentrated to afford the title compound (603 mg, 1.33 mmol, 79%).
[242] Reference Example 17:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid
[243] Sodium dihydrogen phosphate (12.0 g, in acetonitrile solution (30.0 ml) of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzaldehyde (5.60 g, 0.0128 mol) 0.100 mol) aqueous solution (10.0 ml), sodium chlorite (5.19 g, 0.0577 mol) aqueous solution (30.0 ml) and hydrogen peroxide solution (1.701 ml, 30%) are added, followed by stirring at room temperature for 5 hours. The reaction solution is diluted with water and then extracted with ethyl acetate. The extract was washed with saturated aqueous hydrosulfite (Na ₂ S ₂ O ₄ ) solution and saturated brine, dried and concentrated to afford the title compound (5.20 g, 0.0115 mol, 90%).
[244] Reference Example 18:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid
[245] Sodium dihydrogen phosphate (4.01 g, in acetonitrile solution (12.0 ml) of 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzaldehyde (1.87 g, 4.28 mmol) 33.42 mmol) aqueous solution (7.0 ml), sodium chlorite (1.74 g, 19.33 mmol) aqueous solution (7.0 ml) and hydrogen peroxide solution (1.89 ml, 30%) are added, followed by stirring at room temperature for 5 hours. The reaction solution is diluted with water and then extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrosulfite (Na ₂ S ₂ O ₄ ) solution and saturated brine, dried and concentrated to give the title compound (1.90 g, 4.20 mmol, 98%).
[246] Reference Example 19:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid methyl ester
[247] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid (525 mg, 1.1615 mmol) was dissolved in methanol (20 ml) and trimethylsilyldiazomethane (15.9) under ice cooling. g, 10% hexane solution, 13.9473 mmol) is added and then stirred at room temperature for 2 hours. Acetic acid (2 ml) is added to the reaction solution, and the residue is left at room temperature for 16 hours to decompose the excess reagent. The reaction solution is concentrated to give the title compound (530 mg, 1.1373 mmol, 98%).
[248] Reference Example 20:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid methyl ester
[249] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid (1.22 g, 2.6548 mmol) was dissolved in methanol (100 ml) and trimethylsilyldiazomethane under ice-cooling ( 36.3 g, 10% hexane solution, 31.8421 mmol) is added and then stirred at room temperature for 2 hours. Acetic acid (0.5 ml) is added to the reaction solution, and the residue is left at room temperature for 16 hours to decompose the excess reagent. The residue obtained by concentrating the reaction solution is purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to give the title compound (1.18 g, 2.5321 mmol, 95%).
[250] Reference Example 21:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid methyl ester
[251] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid (652 mg, 1.4424 mmol) is dissolved in methylene chloride (20 ml) and anhydrous methanol (231 mg, 7.2187 mmol) , 4-dimethylaminopyridine (264 mg, 2.1639 mmol) and WSC-HCl (830 mg, 4.3296 mmol) were added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1) to afford the title compound (490 mg, 1.0515 mmol, 73%).
[252] Reference Example 22:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzoic acid methyl ester
[253] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid methyl ester (530 mg, 1.1373 mmol) is dissolved in methanol (20 ml) and 10% palladium-carbon (100 mg) ) Is added to a methanol (20 ml) suspension and then stirred for 16 h at room temperature under a hydrogen atmosphere. The reaction solution is filtered and the filtrate is concentrated under reduced pressure to give the title compound (414 mg, 1.101 mmol, 97%).
[254] Reference Example 23:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzoic acid methyl ester
[255] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid methyl ester (15.0 g, 32.1459 mmol) is dissolved in methanol (200 ml) and 10% palladium-carbon ( 1.0 g) of methanol (200 ml) suspension is added and then stirred for 16 h at room temperature under a hydrogen atmosphere. The reaction solution is filtered and the filtrate is concentrated under reduced pressure to give the title compound (11.2 g, 29.7340 mmol, 92%).
[256] Reference Example 24:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzoic acid methyl ester
[257] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-benzyloxybenzoic acid methyl ester (343 mg, 0.7360 mmol) was dissolved in methanol (10 ml) and 10% palladium-carbon (10 mg) ) Is added to a methanol (40 ml) suspension and then stirred for 16 h at room temperature under a hydrogen atmosphere. The reaction solution is filtered and the filtrate is concentrated under reduced pressure to give the title compound (223 mg, 0.5930 mmol, 81%).
[258] Reference Example 25:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester
[259] 4-dimethylaminopyridine (77 mg) in anhydrous methylene chloride solution (10 ml) of 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzoic acid methyl ester (l75 mg, 0.4654 mmol) , 0.6311 mmol), triethylamine (85 mg, 0.8415 mmol) and trifluoromethanesulfonic anhydride (177 mg, 0.6276 mmol) were added, followed by stirring under ice cooling for 3 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 6: 1) to afford the title compound (160 mg, 0.3149 mmol, 68%).
[260] Reference Example 26:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester
[261] In anhydrous methylene chloride solution (200 ml) of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzoic acid methyl ester (3.10 g, 8.2446 mmol), 4-dimethylaminopyridine ( 1.51 g, 12.377 mmol), triethylamine (1.67 g, 16.5346 mmol) and trifluoromethanesulfonic anhydride (3.49 g, 12.3758 mmol) were added, followed by stirring for 3 hours under ice-cooling. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 6: 1) to afford the title compound (4.06 g, 7.9921 mmol, 97%).
[262] Reference Example 27:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester
[263] 4-dimethylaminopyridine (263 mg) in anhydrous methylene chloride solution (30 ml) of 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-hydroxybenzoic acid methyl ester (540 mg, 1.4361 mmol) , 2.1557 mmol), triethylamine (290 mg, 2.8712 mmol) and trifluoromethanesulfonic anhydride (607 mg, 2.1524 mmol) were added, followed by stirring under ice cooling for 3 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 6: 1) to afford the title compound (701 mg, 1.3799 mmol, 96%).
[264] Example 1:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid methyl ester
[265] To a solution of 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (102 mg, 0.2007 mmol) in toluene (2.3 ml) Keystriphenylphosphinepalladium (4.6 mg, 0.0039 mmol), aqueous sodium carbonate solution (2M aqueous solution, 0.35 ml), ethanol solution of lithium chloride (l7 mg, 0.4010 mmol) and benzeneboronic acid (27 mg, 0.2214 mmol) (1.Oml) After the addition, the mixture was heated and stirred at 95 ° C. for 16 hours. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 6: 1) to afford the title compound (84 mg, 0.1926 mmol, 96%).
[266] Example 2:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester
[267] Tetrakis in a toluene (6 ml) solution of 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methylester (333 mg, 0.6555 mmol) Triphenylphosphine palladium (23 mg, 0.0199 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 1.00 ml), lithium chloride (56 mg, 1.3241 mmol) and pyridine-3-boronic acid 1,3-propanediol cyclic ester (159 mg, 0.9814 mmol) ethanol solution (1.3 ml) was added and then stirred at 95 ° C. for 16 h. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (284 mg, 0.6498 mmol, 99%).
[268] Example 3:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid methyl ester
[269] Tetrakis in a toluene (12 ml) solution of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -3- (trifluoromethanesulfonyl) oxybenzoic acid methylester (444 mg, 0.8740 mmol) Triphenylphosphine palladium (60 mg, 0.0519 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 1.35 ml), ethanol solution of lithium chloride (89 mg, 2.0995 mmol) and benzeneboronic acid (320 mg, 2.6244 mmol) (2.1 ml) was added. Heat stir at 95 ° C. for 16 hours. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1) to give the title compound (349 mg, 0.8004 mmol, 68%).
[270] Example 4:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester
[271] Toluene (32 ml) solution of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (1.43 g, 2.8149 mmol) Keystriphenylphosphinepalladium (98 mg, 0.0848 mmol), aqueous sodium carbonate solution (2M aqueous solution, 3.66 ml), lithium chloride (239 mg, 5.6381 mmol) and pyridine-3-boronic acid 1,3-propanediol cyclic ester (684 mg, 4.2222 mmol) ethanol solution (5.9 ml) was added, followed by heating and stirring at 95 ° C. for 16 hours. The reaction solution is diluted with ethyl acetate (200 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to afford the title compound (1.20 g, 2.7459 mmol, 98%).
[272] Example 5:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid methyl ester
[273] Toluene (32 ml) solution of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (1.43 g, 2.8149 mmol) Of keetriphenylphosphinepalladium (98 mg, 0.0848 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 3.66 ml), lithium chloride (239 mg, 5.6381 mmol) and pyridine-4-boronic acid pinacol cyclic ester (866 mg, 4.2243 mmol) Ethanol solution (5.9 ml) was added, followed by heating and stirring at 95 ° C. for 16 h. The reaction solution is diluted with ethyl acetate (200 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to afford the title compound (910 mg, 2.0823 mmol, 74%).
[274] Example 6:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-methoxyphenyl) benzoic acid methyl ester
[275] Tetrakis in a toluene (12 ml) solution of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (411 mg, 0.8090 mmol) Ethanol solution (2.0 ml) of triphenylphosphinepalladium (60 mg, 0.0519 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 1.35 ml), lithium chloride (89 mg, 2.0995 mmol) and 4-methoxybenzeneboronic acid (369 mg, 2.4282 mmol) ) Is added, followed by heating and stirring at 95 ° C. for 16 hours. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1) to give the title compound (351 mg, 0.7532 mmol, 93%).
[276] Example 7:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-methoxyphenyl) benzoic acid methyl ester
[277] To a solution of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (1.50 g, 2.9527 mmol) in toluene (40 ml) Ethanol solution of keystriphenylphosphinepalladium (205 mg, 0.1774 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 4.58 ml), lithium chloride (300 mg, 7.0771 mmol) and 3-methoxybenzeneboronic acid (1.34 g, 8.8186 mmol) 7.2 ml) is added, followed by stirring at 95 ° C. for 16 h. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1) to afford the title compound (1.23 g, 2.6394 mmol, 89%).
[278] Example 8:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (2-methoxyphenyl) benzoic acid methyl ester
[279] To a solution of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (1.50 g, 2.9527 mmol) in toluene (40 ml) Ethanol solution of keystriphenylphosphinepalladium (205 mg, 0.1774 mmol), aqueous sodium carbonate (2 M aqueous solution, 4.58 ml), lithium chloride (300 mg, 7.0771 mmol) and 2-methoxybenzeneboronic acid (1.34 g, 8.8186 mmol) 7.2 ml) is added, followed by stirring at 95 ° C. for 16 h. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1) to afford the title compound (1.34 g, 2.8755 mmol, 97%).
[280] Example 9:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester
[281] To a solution of 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (316 mg, 0.6220 mmol) in toluene (7.1 ml) Keystriphenylphosphinepalladium (22 mg, 0.0190 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 0.81 ml), lithium chloride (53 mg, 1.2502 mmol) and pyridine-3-boronic acid 1,3-propanediol cyclic ester (151 mg, 0.9320 mmol) of ethanol solution (1.3 ml) is added, followed by stirring at 95 ° C. for 16 hours. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (231 mg, 0.5286 mmol, 85%).
[282] Example 10:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid methyl ester
[283] To a solution of 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (trifluoromethanesulfonyl) oxybenzoic acid methyl ester (385 mg, 0.7578 mmol) in toluene (8.6 ml) Of the keystriphenylphosphinepalladium (26 mg, 0.0224 mmol), aqueous sodium carbonate solution (2 M aqueous solution, 0.99 ml), lithium chloride (64 mg, 1.5097 mmol) and pyridine-4-boronic acid pinacol cyclic ester (233 mg, 1.1365 mmol) Ethanol solution (1.59 ml) is added and then heated and stirred at 95 ° C. for 16 h. The reaction solution is diluted with ethyl acetate (100 ml), washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (301 mg, 0.6887 mmol, 91%).
[284] Example 11:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid
[285] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid methyl ester (84 mg, 0.1926 mmol) was dissolved in 1N aqueous sodium hydroxide solution (5 ml) and 1,4-dioxane (5 ml ) Is dissolved in a mixed solution and stirred at room temperature for 16 hours. The reaction solution is diluted with water (20 ml), washed with ether, acidified by addition of concentrated hydrochloric acid, and ether extracted. The extract is washed with water, dried and the solvent is distilled off to give the title compound (45 mg, 0.1800 mmol, 93%).
[286] Example 12:4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid
[287] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester (70 mg, 0.1601 mmol) in 1N aqueous sodium hydroxide solution (5 ml) and 1,4 Dissolve in a mixed solution of dioxane (5 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (20 ml), washed with ether, acidified by addition of concentrated hydrochloric acid, and ether extracted. The extract is washed with water, dried and the solvent is distilled off to give the title compound (45 mg, 0.1063 mmol, 66%).
[288] Example 13:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid
[289] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid methyl ester (349 mg, 0.8004 mmol) in 1N aqueous sodium hydroxide solution (10 ml) and 1,4-dioxane (20 ml ) Is dissolved in a mixed solution and stirred at room temperature for 16 hours. The reaction solution is diluted with water (100 ml), washed with ether, acidified by addition of concentrated hydrochloric acid, and ether extracted. The extract is washed with water, dried and the solvent is distilled off to give the title compound (340 mg, 0.7819 mmol, 98%).
[290] Example 14:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid
[291] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester (1.20 g, 2.7459 mmol) was mixed with 1N aqueous sodium hydroxide solution (13.7 ml) and 1 Dissolve in a mixed solution of, 4-dioxane (30 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (200 ml) and washed with ether, and then concentrated with hydrochloric acid to make acid and extracted with ether. The extract is washed with water, dried and the solvent is distilled off to give the title compound (1.02 g, 2.4113 mmol, 88%).
[292] Example 15:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid
[293] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid methyl ester (910 mg, 2.0823 mmol) was mixed with 1N aqueous sodium hydroxide solution (10.4 ml) and 1, Dissolve in a mixed solution of 4-dioxane (25 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (200 ml) and washed with ether, and then concentrated with hydrochloric acid to make acid and extracted with ether. The extract is washed with water, dried and the solvent is distilled off to give the title compound (655 mg, 1.5484 mmol, 74%).
[294] Example 16:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-methoxyphenyl) benzoic acid
[295] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-methoxyphenyl) benzoic acid methyl ester (472 mg, 1.0128 mmol) was mixed with 1N aqueous sodium hydroxide solution (10 ml) and 1, Dissolve in a mixed solution of 4-dioxane (20 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (100 ml), washed with ether, acidified by addition of concentrated hydrochloric acid, and ether extracted. The extract is washed with water, dried and the solvent is distilled off to give the title compound (440 mg, 0.9734 mmol, 96%).
[296] Example 17:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-methoxyphenyl) benzoic acid
[297] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-methoxyphenyl) benzoic acid methyl ester (1.23 g, 2.6394 mmol) was mixed with 1N aqueous sodium hydroxide solution (20 ml) and 1 Dissolve in a mixed solution of, 4-dioxane (40 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (200 ml) and washed with ether, and then concentrated with hydrochloric acid to make acid and extracted with ether. The extract is washed with water, dried and the solvent is distilled off to give the title compound (1.03 g, 2.2787 mmol, 86%).
[298] Example 18:5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (2-methoxyphenyl) benzoic acid
[299] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (2-methoxyphenyl) benzoic acid methyl ester (1.34 g, 2.8755 mmol) was mixed with 1N aqueous sodium hydroxide solution (20 ml) and 1 Dissolve in a mixed solution of, 4-dioxane (40 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (200 ml) and washed with ether, and then concentrated with hydrochloric acid to make acid and extracted with ether. The extract is washed with water, dried and the solvent is distilled off to give the title compound (1.21 g, 2.6769 mmol, 93%).
[300] Example 19:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid
[301] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid methyl ester (231 mg, 0.5286 mmol) in 1N aqueous sodium hydroxide solution (10 ml) and 1,4 Dissolve in a mixed solution of dioxane (10 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (200 ml), washed with ether, and concentrated with hydrochloric acid to make acid, followed by ether extraction. The extract is washed with water, dried and the solvent is distilled off to give the title compound (170 mg, 0.4018 mmol, 76%).
[302] Example 20:3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid
[303] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid methyl ester (301 mg, 0.5508 mmol) was added with 1N aqueous sodium hydroxide solution (10 ml) and 1,4. Dissolve in a mixed solution of dioxane (10 ml) and stir at room temperature for 16 hours. The reaction solution is diluted with water (100 ml), washed with ether, acidified by addition of concentrated hydrochloric acid, and ether extracted. The extract is washed with water, dried and the solvent is distilled off to give the title compound (233 mg, 0.5508 mmol, 80%).
[304] Example 21:N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine
[305] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (60 mg, 0.1415 mmol), 4-dimethylaminopyridine (8.6 mg, 0.0704 mmol) and Piperidine (24 mg, 0.2823 mmol) is dissolved in methylene chloride (5 ml), WSC-HCl (81 mg, 0.4225 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (62 mg, 0.1265 mmol, 89%).
[306] Example 22:N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] morpholine
[307] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (7 mg, 0.0165 mmol), 4-dimethylaminopyridine (1.0 mg, 0.0081 mmol) and Morpholine (2.9 mg, 0.0333 mmol) is dissolved in methylene chloride (2 ml), WSC-HCl (9.5 mg, 0.0495 mmol) is added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (8.0 mg, 0.0162 mmol, 98%).
[308] Example 23:N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-trifluoroaniline
[309] 4-trifluoromethyl in methylene chloride solution (10 ml) of 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (82 mg, 0.1933 mmol) Aniline (47 mg, 0.2919 mmol), triethylamine (39 mg, 0.3861 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (98 mg, 0.5798 mmol) were added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (58 mg, 0.1024 mmol, 53%).
[310] Example 24:N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-piperidine
[311] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (80 mg, 0.1886 mmol), 4-dimethylaminopyridine (12 mg, 0.0983 mmol) and blood Ferridine (32 mg, 0.3764 mmol) is dissolved in methylene chloride (10 ml), WSC-HCl (109 mg, 0.5685 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (45 mg, 0.0918 mmol, 49%).
[312] Example 25:N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] morpholine
[313] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (80 mg, 0.1886 mmol), 4-dimethylaminopyridine (12 mg, 0.0983 mmol) and mor Pauline (33 mg, 0.3793 mmol) is dissolved in methylene chloride (10 ml), WSC-HCl (109 mg, 0.5685 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (51 mg, 0.1036 mmol, 55%).
[314] Example 26:N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline
[315] 4-trifluoromethyl in methylene chloride solution (5 ml) of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (85 mg, 0.2004 mmol) Aniline (48 mg, 0.2981 mmol), triethylamine (41 mg, 0.4059 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (102 mg, 0.6035 mmol) were added and then stirred at room temperature for 3 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (60 mg, 0.1060 mmol, 53%).
[316] Example 27:N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] piperidine
[317] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (430 mg, 1.0165 mmol) and piperidine (173 mg, 2.0352 mmol) were treated with methylene chloride ( 30 ml), 4-dimethylaminopyridine (62 mg, 0.5081 mmol) and WSC-HCl (487 mg, 2.5404 mmol) are added, followed by stirring at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (334 mg, 0.6816 mmol, 67%).
[318] Example 28:N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] morpholine
[319] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and morpholine (44 mg, 0.5057 mmol) in methylene chloride (20 ml ), WSC-HCl (122 mg, 0.6364 mmol) is added and stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (102 mg, 0.2073 mmol, 88%).
[320] Example 29:N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline
[321] 4-trifluoromethyl in methylene chloride solution (10 ml) of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (200 mg, 0.4716 mmol) Aniline (114 mg, 0.7080 mmol), triethylamine (95 mg, 0.9405 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (239 mg, 1.4142 mmol) were added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (166 mg, 0.2932 mmol, 62%).
[322] Example 30:N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine
[323] Methyl chloride of 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (21 mg, 0.0496 mmol) and piperidine (8.4 mg, 0.0988 mmol) (3 ml), WSC-HCl (29 mg, 0.1512 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (11 mg, 0.0224 mmol, 45%).
[324] Example 31:(S) -N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -1-phenylethylamine
[325] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (17 mg, 0.0401 mmol) and (S) -phenethylamine (9.7 mg, 0.0801 mmol ) Is dissolved in methylene chloride (5 ml), WSC-HCl (23 mg, 0.1199 mmol) is added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (10 mg, 0.0190 mmol, 47%).
[326] Example 32:N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] piperidine
[327] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (21 mg, 0.0496 mmol) and piperidine (8.4 mg, 0.0988 mmol) in methylene chloride (3 ml), WSC-HCl (29 mg, 0.1512 mmol) is added and stirred for 16 h at room temperature. The reaction is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (8.2 mg, 0.0167 mmol, 34%).
[328] Example 33:(S) -N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -1-phenylethylamine
[329] 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (24 mg, 0.0567 mmol) and (S) -phenethylamine (14 mg, 0.1157 mmol) Is dissolved in methylene chloride (5 ml), WSC-HCl (33 mg, 0.1721 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (15.9 mg, 0.0302 mmol, 53%).
[330] Example 34:N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline
[331] 4-trifluoromethyl in methylene chloride solution (3 ml) of 3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (18 mg, 0.0424 mmol) Aniline (10.2 mg, 0.0633 mmol), triethylamine (8.6 mg, 0.0851 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (21.5 mg, 0.1272 mmol) were added followed by 16 h at room temperature. Stir. The reaction solution is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (17 mg, 0.0300 mmol, 71%).
[332] Example 35:4- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid
[333] 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid (76 mg, 1.1800 mmol) is dissolved in a mixed solvent of acetonitrile (3 ml) and water (l ml), and room temperature Add CAN (247 mg, 0.4507 mmol) and stir for 1 hour. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (54 mg, 0.1377 mmol, 77%).
[334] Example 36:4- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid
[335] A mixed solvent of 4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (30 mg, 1.1820 mmol) with acetonitrile (6 ml) and water (2 ml) Dissolved in, added CAN (97 mg, 0.1770 mmol) at room temperature, and stirred for 3 hours. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (10% methanol-methylene chloride) to afford the title compound (10 mg, 0.0254 mmol, 36%).
[336] Example 37:5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid
[337] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2-phenylbenzoic acid (340 mg, 0.7819 mmol) is dissolved in a mixed solvent of acetonitrile (30 ml) and water (10 ml), and room temperature Add CAN (1.10g, 2.0072mmol) at, and stir for 3 hours. The reaction solution is poured into water and ether extracted. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (234 mg, 0.5969 mmol, 76%).
[338] Example 38:5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid
[339] A mixed solvent of 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoic acid (500 mg, 1.1820 mmol) with acetonitrile (30 ml) and water (10 ml) Dissolve in, add CAN (1.62 g, 2.9562 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water, the reaction solution is neutralized with 1N aqueous sodium hydroxide solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (10% methanol-methylene chloride) to afford the title compound (270 mg, 0.6870 mmol, 58%).
[340] Example 39:5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoic acid
[341] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (500 mg, 1.1820 mmol) in tetrahydrofuran (THF) solution (20 ml) Tertiary butyl-1,3-diisopropylisourea (2.36 g, 11.8 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to give 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-Pyridyl) benzoic acid tertiary butyl ester (400 mg, 0.8350 mmol, 70%) is obtained. The compound is dissolved in a mixed solvent of acetonitrile (30 ml) and water (10 ml), CAN (1.12 g, 2.0437 mmol) is added at room temperature and then stirred for 3 hours.
[342] The reaction solution is poured into water, the reaction solution is neutralized with 1N aqueous sodium hydroxide solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by silica gel column chromatography (methylene chloride: methanol = 95: 5) to give 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) -2- ( 4-pyridyl) benzoic acid tertiary butyl ester (251 mg, 0.5590 mmol, 67%) is obtained. The compound (251 mg, 0.5590 mmol) is dissolved in formic acid (10 ml) and stirred at room temperature for 6 hours. The residue obtained by distilling off the solvent was washed with ether to give the title compound (202 mg, 0.5139 mmol, 92%). (Total yield: 43%)
[343] Example 40:5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoic acid
[344] Mixing 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-methoxyphenyl) benzoic acid (440 mg, 0.9734 mmol) with acetonitrile (30 ml) and water (10 ml) Dissolve in solvent, add CAN (1.10 g, 2.0072 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and ether extracted. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (259 mg, 0.6137 mmol, 63%).
[345] Example 41:5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoic acid
[346] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-methoxyphenyl) benzoic acid (1.03 g, 2.2787 mmol) was dissolved in acetonitrile (30 ml) and water (10 ml). Dissolve in mixed solvent, add CAN (3.12 g, 5.6934 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and ether extracted. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (817 mg, 1.9360 mmol, 85%).
[347] Example 42:5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (2-methoxyphenyl) benzoic acid
[348] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (2-methoxyphenyl) benzoic acid (1.21 g, 2.6769 mmol) was dissolved in acetonitrile (30 ml) and water (10 ml). Dissolve in mixed solvent, add CAN (3.60 g, 6.6914 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and ether extracted. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (5% methanol-methylene chloride) to afford the title compound (859 mg, 2.0355 mmol, 76%).
[349] Example 43:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] piperidine
[350] 4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (18 mg, 0.0459 mmol) and piperidine (5.9 mg, 0.0692 mmol) were methylene Dissolve in chloride (3 ml), add WSC-HCl (22 mg, 0.1147 mmol) and stir at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (12 mg, 0.0261 mmol, 57%).
[351] Example 44:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] morpholine
[352] 4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (18 mg, 0.0459 mmol) and morpholine (6 mg, 0.0689 mmol) were added to methylene chloride ( 3 ml), WSC-HCl (22 mg, 0.1147 mmol) is added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 1: 1) to afford the title compound (10 mg, 0.0216 mmol, 47%).
[353] Example 45:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] -4-trifluoromethylaniline
[354] 4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (16 mg, 0.0408 mmol) is dissolved in methylene chloride (3 ml) and 4 at room temperature Trifluoromethylaniline (13 mg, 0.0807 mmol), triethylamine (8.2 mg, 0.0811 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (21 mg, 0.1242 mmol) were added and then 16 hours Stir while. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 1: 1) to afford the title compound (8 mg, 0.0149 mmol, 37%).
[355] Example 46:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] piperidine
[356] N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine (70 mg, 0.1428 mmol) with acetonitrile (6 ml) Dissolve in a mixed solvent of water (2 ml), add CAN (231 mg, 0.4293 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (26 mg, 0.0565 mmol, 40%).
[357] Example 47:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] morpholine
[358] N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] morpholine (8 mg, 0.0162 mmol) with acetonitrile (3 ml) and water Dissolve in (1 ml) of mixed solvent, add CAN (26 mg, 0.0483 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (4.5 mg, 0.0097 mmol, 60%).
[359] Example 48:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline
[360] N- [4- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline (55 mg, 0.0971 mmol) was aceto Dissolve in a mixed solvent of nitrile (3 ml) and water (1 ml), add CAN (157 mg, 0.2918 mmol) at room temperature and stir for 2 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (10 mg, 0.0186 mmol, 19%).
[361] Example 49:N- [4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-methoxyaniline
[362] Dissolve 4- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid (44 mg, 0.1119 mmol) in methylene chloride (10 ml) At room temperature, p-anisidine (28 mg, 0.2276 mmol), triethylamine (23 mg, 0.2277 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (38 mg, 0.1982 mmol) were added, followed by 16 Stir for hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (33 mg, 0.0662 mmol, 59%).
[363] Example 50:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] piperidine
[364] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (40 mg, 0.1020 mmol), 4-dimethylaminopyridine (6.2 mg, 0.0508 mmol) And piperidine (17 mg, 0.2000 mmol) is dissolved in methylene chloride (5 ml), WSC-HCl (59 mg, 0.3077 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 2: 1) to afford the title compound (16 mg, 0.0348 mmol, 34%).
[365] Example 51:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] morpholine
[366] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (40 mg, 0.1020 mmol), 4-dimethylaminopyridine (6.2 mg, 0.0508 mmol) And morpholine (18 mg, 0.2068 mmol) is dissolved in methylene chloride (5 ml), WSC-HCl (59 mg, 0.3077 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (13 mg, 0.0281 mmol, 28%).
[367] Example 52:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] -4-methoxyaniline
[368] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (33 mg, 0.0841 mmol) is dissolved in methylene chloride (3 ml) and p at room temperature -Anisidine (21 mg, 0.1707 mmol), triethylamine (34 mg, 0.3366 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (57 mg, 0.3372 mmol) were added and then stirred for 16 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 1) to afford the title compound (28 mg, 0.0563 mmol, 67%).
[369] Example 53:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoyl] -4-trifluoromethylaniline
[370] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2-phenylbenzoic acid (40 mg, 0.1020 mmol) is dissolved in methylene chloride (5 ml) and 4 at room temperature Trifluoromethylaniline (25 mg, 0.1552 mmol), triethylamine (21 mg, 0.2079 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (52 mg, 0.3076 mmol) were added and then 16 hours Stir. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 3: 1) to afford the title compound (5 mg, 0.0093 mmol, 9%).
[371] Example 54:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] piperidine
[372] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine (33 mg, 0.0673 mmol) with acetonitrile (6 ml) Dissolve in a mixed solvent of water (2 ml), add CAN (92 mg, 0.1678 mmol) at room temperature and stir for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (methylene chloride: methanol = 95: 5) to afford the title compound (20 mg, 0.0434 mmol, 64%).
[373] Example 55:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] morpholine
[374] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid (40 mg, 0.1017 mmol) and morpholine (18 mg, 0.2608 mmol ) Is dissolved in methylene chloride (3 ml), WSC-HCl (49 mg, 0.2556 mmol) is added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (methylene chloride: methanol = 95: 5) to give the title compound (32 mg, 0.0692 mmol, 68%).
[375] Example 56:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-methoxyaniline
[376] Dissolve 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoic acid (73 mg, 0.1857 mmol) in methylene chloride (5 ml) At room temperature, p-anisidine (46 mg, 0.3739 mmol), triethylamine (75 mg, 0.7425 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (126 mg, 0.7455 mmol) were added, followed by 16 Stir for hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 4) to afford the title compound (33 mg, 0.0662 mmol, 36%).
[377] Example 57:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline
[378] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -4-trifluoromethylaniline (60 mg, 0.1060 mmol) in aceto Dissolve in a mixed solvent of nitrile (9 ml) and water (3 ml), add CAN (228 mg, 0.4237 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (18 mg, 0.0335 mmol, 32%).
[379] Example 58:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] piperidine (methanesulfonate)
[380] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] piperidine (630 mg, 1.2857 mmol) with acetonitrile (30 ml) Dissolve in a mixed solvent of water (10 ml), add CAN (1.73 g, 3.1569 mmol) at room temperature and stir for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (methylene chloride: methanol = 95: 5) to give the title compound (470 mg, 0.1217 mmol, 79%). The compound (470 mg, 0.1217 mmol) is dissolved in anhydrous methylene chloride, treated with 1 equivalent of methanesulfonic acid and then concentrated. The residue is recrystallized from a mixed solvent of ethyl acetate toluene ether to give methanesulfonic acid salt (450 mg) of the title compound.
[381] Example 59:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] morpholine
[382] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] morpholine (102 mg, 0.2073 mmol) with acetonitrile (15 ml) and water Dissolve in (5 ml) of mixed solvent, add CAN (279 mg, 0.5091 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water, neutralized with 1N aqueous sodium hydroxide solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (methylene chloride: methanol = 95: 5) to give the title compound (60 mg, 0.1298 mmol, 63%).
[383] Example 60:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -4-methoxyaniline
[384] Dissolve 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoic acid (100 mg, 0.2544 mmol) in methylene chloride (30 ml) At room temperature, p-anisidine (56 mg, 0.4552 mmol), triethylamine (75 mg, 0.7425 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (126 mg, 1.3663 mmol) were added, followed by 16 Stir for hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 4) to afford the title compound (33 mg, 0.0963 mmol, 38%).
[385] Example 61:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline
[386] N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline (140 mg, 0.2473 mmol) was aceto Dissolve in a mixed solvent of nitrile (9 ml) and water (3 ml), add CAN (399 mg, 0.7416 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to give the title compound (60 mg, 0.1119 mmol, 45%).
[387] Example 62:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoyl] piperidine
[388] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoic acid (50 mg, 0.1184 mmol) and piperidine (20 mg, 0.2352 mmol) is dissolved in methylene chloride (30 ml), WSC-HCl (68 mg, 0.3547 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (23 mg, 0.0468 mmol, 40%).
[389] Example 63:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoyl] morpholine
[390] 5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoic acid (50 mg, 0.1184 mmol) and morpholine (21 mg, 0.2413 mmol) is dissolved in methylene chloride (30 ml), WSC-HCl (68 mg, 0.3547 mmol) is added and then stirred at room temperature for 16 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (hexane: ethyl acetate = 1: 1) to afford the title compound (30 mg, 0.0613 mmol, 52%).
[391] Example 64:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoyl] -4-methoxyaniline
[392] 5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-methoxyphenyl) benzoic acid (100 mg, 0.2369 mmol) was added to methylene chloride (20 ml). Dissolve, add p-anisidine (58 mg, 0.4715 mmol), triethylamine (48 mg, 0.4752 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (80 mg, 0.4733 mmol) at room temperature, Stir for 16 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer silica gel (hexane: ethyl acetate = 1: 1) to afford the title compound (78 mg, 0.1480 mmol, 62%).
[393] Example 65:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoyl] piperidine
[394] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoic acid (100 mg, 0.2369 mmol) and piperidine (40 mg, 0.4705 mmol) is dissolved in methylene chloride (20 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (136 mg, 0.7094 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (58 mg, 0.1186 mmol, 50%).
[395] Example 66:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoyl] morpholine
[396] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoic acid (100 mg, 0.2369 mmol) and morpholine (41 mg, 0.4712 mmol) is dissolved in methylene chloride (20 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (136 mg, 0.7094 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue is purified by silica gel column chromatography (hexane: ethyl acetate = 1: 3) to afford the title compound (80 mg, 0.1629 mmol, 69%).
[397] Example 67:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoyl] -4-methoxyaniline
[398] 5- (5,6-Dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-methoxyphenyl) benzoic acid (100 mg, 0.2369 mmol) in methylene chloride (20 ml) Dissolve, add p-anisidine (58 mg, 0.4715 mmol), triethylamine (48 mg, 0.4752 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (80 mg, 0.4733 mmol) at room temperature, Stir for 16 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 1) to give the title compound (68 mg, 0.1290 mmol, 54%).
[399] Example 68:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (2-methoxyphenyl) benzoyl] -4-methoxyaniline
[400] 5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (2-methoxyphenyl) benzoic acid (66 mg, 0.1563 mmol) in methylene chloride (5 ml) Dissolve and add p-anisidine (38 mg, 0.3089 mmol), triethylamine (47 mg, 0.4653 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride (53 mg, 0.3136 mmol) at room temperature, Stir for 16 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 1) to give the title compound (38 mg, 0.0721 mmol, 46%).
[401] Example 69:N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] piperidine
[402] N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] piperidine (80 mg, 0.1632 mmol) with acetonitrile (9 ml) Dissolve in a mixed solvent of water (3 ml), add CAN (128 mg, 0.2335 mmol) at room temperature and stir for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 3) to afford the title compound (51 mg, 0.1108 mmol, 68%). The compound is converted to methanesulfonate according to the method of Example 58.
[403] Example 70:(S) -N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (3-pyridyl) benzoyl] -1-phenylethylamine
[404] (S) -N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (3-pyridyl) benzoyl] -1-phenylethylamine (69 mg, 0.1311 mmol) Was dissolved in a mixed solvent of acetonitrile (9 ml) and water (3 ml), and CAN (180 mg, 0.3284 mmol) was added at room temperature, followed by stirring for 3 hours. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 3) to afford the title compound (48 mg, 0.0967 mmol, 74%).
[405] Example 71:N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] piperidine
[406] N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] piperidine (74 mg, 0.1510 mmol) with acetonitrile (9 ml) Dissolve in a mixed solvent of water (3 ml), add CAN (206 mg, 0.3759 mmol) at room temperature and stir for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin silica gel (hexane: ethyl acetate = 1: 5) to afford the title compound (32 mg, 0.0695 mmol, 46%).
[407] Example 72:(S) -N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-phenylethylamine
[408] (S) -N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -1-phenylethylamine (64 mg, 0.1216 mmol) Was dissolved in a mixed solvent of acetonitrile (9 ml) and water (3 ml), and CAN (166 mg, 0.3029 mmol) was added at room temperature, followed by stirring for 3 hours. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 3) to afford the title compound (30 mg, 0.0604 mmol, 50%).
[409] Example 73:N- [3- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline
[410] N- [3- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoyl] -4-trifluoromethylaniline (17 mg, 0.0300 mmol) was aceto Dissolve in a mixed solvent of nitrile (6 ml) and water (2 ml), add CAN (48 mg, 0.0892 mmol) at room temperature and stir for 3 hours. The reaction solution is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer chromatography (methylene chloride: methanol = 95: 5) to afford the title compound (6 mg, 0.0111 mmol, 37%).
[411] Example 74:(S) -N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-phenylethylamine (Methanesulfonate)
[412] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and (S) -1-phenylethylamine (93 mg, 0.7674 mmol) is dissolved in methylene chloride (10 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (146 mg, 0.7616 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off.
[413] The residue was purified by silica gel column chromatography (methylene chloride: methanol = 95: 5) to give (S) -N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2 Obtain-(4-pyridyl) benzoyl] -1-phenylethylamine (90 mg, 0.1711 mmol, 72%). The compound (102 mg, 0.2073 mmol) is dissolved in a mixed solvent of acetonitrile (15 ml) and water (5 ml), CAN (279 mg, 0.5091 mmol) is added at room temperature, and then stirred for 3 hours. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 5) to afford the title compound (55 mg, 0.1298 mmol, 63%). The compound is converted to methanesulfonate according to the method of Example 58.
[414] Example 75:(R) -N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-phenylethylamine (Methanesulfonate)
[415] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and (R) -1-phenylethylamine (93 mg, 0.7674 mmol) is dissolved in methylene chloride (10 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (146 mg, 0.7616 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off.
[416] The residue was purified by silica gel column chromatography (methylene chloride: methanol = 95: 5) to give (R) -N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2 Obtain-(4-pyridyl) benzoyl] -1-phenylethylamine (98 mg, 0.1863 mmol, 79%). The compound (98 mg, 0.1863 mmol) was dissolved in a mixed solvent of acetonitrile (15 ml) and water (5 ml), and CAN (251 mg, 0.4580 mmol) was added at room temperature, followed by stirring for 3 hours. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue was purified by preparative thin silica gel (hexane: ethyl acetate = 1: 5) to afford the title compound (60 mg, 0.1209 mmol, 65%). The compound is converted to methanesulfonate according to the method of Example 58.
[417] Example 76:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] cyclohexylamine (methanesulfonate)
[418] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and cyclohexylamine (76 mg, 0.7663 mmol) were added to methylene chloride ( 10 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (146 mg, 0.7616 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off.
[419] The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 5) to give N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4- Pyridyl) benzoyl] cyclohexylamine (58 mg, 0.1149 mmol, 49%) is obtained. The compound (58 mg, 0.1150 mmol) was dissolved in a mixed solvent of acetonitrile (9 ml) and water (3 ml), and CAN (155 mg, 0.2828 mmol) was added at room temperature, followed by stirring for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin layer silica gel (methylene chloride: methanol = 95: 5) to afford the title compound (35 mg, 0.0738 mmol, 64%). The compound is converted to methanesulfonate according to the method of Example 58.
[420] Example 77:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] cyclopentylamine (methanesulfonate)
[421] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and cyclopentylamine (65 mg, 0.7633 mmol) were added to methylene chloride ( 10 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (146 mg, 0.7616 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off.
[422] The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 5) to give N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4- Pyridyl) benzoyl] cyclopentylamine (58 mg, 0.1182 mmol, 50%) is obtained. The compound (58 mg, 0.1183 mmol) was dissolved in a mixed solvent of acetonitrile (9 ml) and water (3 ml), and CAN (155 mg, 0.2901 mmol) was added at room temperature, followed by stirring for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin silica gel (5% methanol-methylene chloride) to afford the title compound (28 mg, 0.0608 mmol, 51%). The compound is converted to methanesulfonate according to the method of Example 58.
[423] Example 78:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] cyclopropylamine (methanesulfonate)
[424] 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and cyclopropylamine (44 mg, 0.7719 mmol) were added to methylene chloride ( 5 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (146 mg, 0.7616 mmol) were added, followed by stirring at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 5) to give N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4- Pyridyl) benzoyl] cyclopropylamine (71 mg, 0.1536 mmol, 65%) is obtained.
[425] The compound (71 mg, 0.1536 mmol) was dissolved in a mixed solvent of acetonitrile (9 ml) and water (3 ml), and CAN (207 mg, 0.3777 mmol) was added at room temperature, followed by stirring for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin silica gel (methylene chloride: methanol = 95: 5) to afford the title compound (51 mg, 0.1180 mmol, 77%). The compound is converted to methanesulfonate according to the method of Example 58.
[426] Example 79:N- [5- (5,6-dimethoxy-3-methyl-1,4-benzoquinone-2-yl) methyl-2- (4-pyridyl) benzoyl] -1-ethylpropylamine (methanesulfonate )
[427] Methyl 5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4-pyridyl) benzoic acid (100 mg, 0.2364 mmol) and 1-ethylpropylamine (66 mg, 0.7586 mmol) Dissolve in chloride (5 ml), 4-dimethylaminopyridine (6 mg, 0.0491 mmol) and WSC-HCl (146 mg, 0.7616 mmol) are added and then stirred at room temperature for 6 hours. The reaction solution is washed with water, dried and the solvent is distilled off. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 5) to give N- [5- (3,4,5,6-tetramethoxy-2-methylbenzyl) -2- (4- Pyridyl) benzoyl] -1-ethylpropylamine (63 mg, 0.1280 mmol, 54%) is obtained.
[428] The compound (63 mg, 0.1280 mmol) was dissolved in a mixed solvent of acetonitrile (9 ml) and water (3 ml), and CAN (172 mg, 0.3777 mmol) was added at room temperature, followed by stirring for 1 hour. The reaction solution is poured into water, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The extract is washed with water, dried and the solvent is distilled off. The residue is purified by preparative thin silica gel (methylene chloride: methanol = 95: 5) to give the title compound (46 mg, 0.0995 mmol, 78%). The compound is converted to methanesulfonate according to the method of Example 58.
[429]
[430]
[431]
[432]
[433]
[434]
[435]
[436]
[437]
[438]
[439]
[440]
[441]
[442]
[443]
[444]
[445]
[446]
[447]
[448]
[449]
[450]
[451]
[452]
[453]
[454]
[455]
[456]
[457]
[458] Experimental Example 1: Response to human lung cancer-derived cell A549 (A549 / NF-κBLuc) stably introduced luciferase plasmid (pNF κB-Luc, Stratadine, USA) controlled by NF-κB binding sequence
[459] Transfection of pNF κB-Luc and pSV2neo (Clontech, USA) simultaneously using a lipofectamine (LifeTech Oriental, Tokyo) in A549 cells (ATCC CCL185), G418 sulfate (1 mg) / ml, LifeTech Oriental Co., Ltd.) is added to the medium to select cells A549 / NF-κBLuc into which pNFκB-Luc is stably introduced.
[460] The compound obtained in Example is added to A549 / NF-κBLuc, and IL-1β capable of activating NF-κB is added 1 hour after the addition, and the culture is continued for 3 hours. It is evident that the compounds obtained in the Examples are indicative of luciferase activity by inhibiting the activation of NF-κB following stimulation of IL-1β. Its IC ₅₀ values are listed in Tables 30 and 31.
[461]
[462]
[1] The present invention relates to novel substituted benzoic acid derivatives and, more particularly, to NF-κB inhibitors comprising the substituted benzoic acid derivatives, their hydroquinone forms or pharmacologically acceptable salts thereof as active ingredients and activation of NF-κB. It relates to a prophylactic or therapeutic agent for diseases caused by.

权利要求:
Claims (15)
[1" claim-type="Currently amended] Novel substituted benzoic acid derivatives of formula (I)
Formula I

In Formula I,
R ¹ is a group of Formula II or Formula III,
R ² is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted,
X is a carboxyl group which may be esterified or amidated.
Formula II

Formula III

In Chemical Formulas II and III,
R ³ , R ⁴ and R ⁵ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms,
R ⁹ and R ¹⁰ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an acyl group having 2 to 11 carbon atoms.
[2" claim-type="Currently amended] The novel substituted benzoic acid derivative according to claim 1, wherein R ¹ is a group of formula II.
Formula II

In Chemical Formula II,
R ³ and R ⁴ are each independently a hydrogen atom, a methyl group or a methoxy group.
[3" claim-type="Currently amended] The novel substituted benzoic acid derivative according to claim 1 or 2, wherein R ¹ is a group of formula II.
Formula II

In Chemical Formula II,
R ⁵ is a hydrogen atom or a methyl group.
[4" claim-type="Currently amended] The novel substituted benzoic acid derivative according to any one of claims 1 to 3, wherein R ² is an optionally substituted aryl group having 6 to 12 carbon atoms or an optionally substituted heteroaryl group having 4 to 11 carbon atoms.
[5" claim-type="Currently amended] The compound according to any one of claims 1 to 4, wherein R ² is a phenyl group, 4-methoxyphenyl group, 3-methoxyphenyl group, 2-methoxyphenyl group, 3,4-dimethoxyphenyl group, 4-pyridyl group, Novel substituted benzoic acid derivatives that are 3-pyridyl, 2-pyridyl, 2-furanyl or 3-furanyl.
[6" claim-type="Currently amended] The compound of any one of claims 1 to 5, wherein X is a group of the formula -COOR ⁶ , wherein R ⁶ is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms which may be substituted, or a 7 to 14 carbon atoms which may be substituted. Substituted arbenzo group).
[7" claim-type="Currently amended] The compound according to any one of claims 1 to 5, wherein X is a group of the formula -CONR ⁷ R ⁸ , wherein R ⁷ and R ⁸ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, An aryl group having 6 to 12 carbon atoms which may be substituted, a heteroaryl group having 4 to 11 carbon atoms which may be substituted, an aralkyl group having 7 to 14 carbon atoms which may be substituted, or a heteroarylalkyl group having 5 to 13 carbon atoms which may be substituted; , R ⁷ and R ⁸ together with the nitrogen atom to which they are attached form a heterocyclic ring which may further contain a nitrogen atom, an oxygen atom or a sulfur atom or may be condensed).
[8" claim-type="Currently amended] 6. The carbon atom and nitrogen of claim 1, wherein X is a group of formula -CONR ⁷ R ⁸ , wherein R ⁷ and R ⁸ together with the nitrogen atom to which they are attached In addition to the atom, it forms a 5-8 membered nitrogen-containing heterocyclic ring which may further contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur atoms, wherein the carbon or sulfur atom on the ring is in oxide form And a new substituted benzoic acid derivative.
[9" claim-type="Currently amended] The novel substituted benzoic acid derivative according to any one of claims 1 to 8, wherein:
Formula I

In Formula I,
R ¹ is a group of formula (II)
R ² is a phenyl group, 4-methoxyphenyl group, 3-methoxyphenyl group, 2-methoxyphenyl group, 3,4-dimethoxyphenyl group, 4-pyridyl group, 3-pyridyl group, 2-pyridyl group, 2-furanyl group Or 3-furanyl group,
X is a carboxyl group which may be esterified or amidated.
Formula II

In Chemical Formula II,
R ³ and R ⁴ are a methyl group or a methoxy group,
R ⁵ is a methyl group.
[10" claim-type="Currently amended] A NF-κB inhibitor comprising as an active ingredient the novel substituted benzoic acid derivatives according to any one of claims 1 to 9, a hydroquinone form thereof or a pharmacologically acceptable salt thereof.
[11" claim-type="Currently amended] The method of claim 10, wherein IL-1, TNF-α, IL-2, IL-6, IL-8, iN0S, granulocyte colony stimulator, interferon-γ, ICAM-1, VCAM-1, ELAM-1, major Histocompatibility antigen class I, major histocompatibility antigen class II, β-2 microglobulin, immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B, complement C4, c-myc, HIV, HTLV-1, NF-κB inhibitor, which is an expression inhibitor of genes of one or more substances selected from the group consisting of SV-40, CMV and adenovirus.
[12" claim-type="Currently amended] The NF-κB inhibitor according to claim 10 or 11, which is an agent for preventing or treating an inflammatory disease.
[13" claim-type="Currently amended] The NF-κB inhibitor according to claim 10 or 11, which is an agent for preventing or treating an autoimmune disease.
[14" claim-type="Currently amended] The NF-κB inhibitor according to claim 10 or 11, which is an agent for preventing or treating a viral disease.
[15" claim-type="Currently amended] A prophylactic or therapeutic agent for a disease caused by the activation of NF-κB, comprising as an active ingredient a novel substituted benzoic acid derivative of Formula I, its hydroquinone form or a pharmacologically acceptable salt thereof.
Formula I

In Formula I,
R ¹ is a group of Formula II or Formula III,
R ² is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted,
X is a carboxyl group which may be esterified or amidated.
Formula II

Formula III

In Chemical Formulas II and III,
R ³ , R ⁴ and R ⁵ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms,
R ⁹ and R ¹⁰ are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an acyl group having 2 to 11 carbon atoms.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6528957B2|2019-06-12|Trk inhibitory compounds

---

US20160122290A1|2016-05-05|Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors

---

JP6160613B2|2017-07-12|Trk inhibitory compound

---

US9663466B2|2017-05-30|Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

---

JP6101675B2|2017-03-22|Compounds for the treatment of metabolic diseases

---

US8946224B2|2015-02-03|Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions

---

DE60222921T2|2008-08-07|Amid derivatives as inhibitors of glycogen synthase kinase-3-beta

---

JP5542809B2|2014-07-09|Organic compounds

---

EP2215049B1|2019-06-12|P2x3, receptor antagonists for treatment of pain

---

EP1465869B1|2013-05-15|Modulators of lxr

---

DE69836378T2|2007-10-11|Benzoic acid and benzamide derivatives of anthranilic acid and their use as MEK inhibitors

---

US6552048B2|2003-04-22|Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals

---

US7179817B2|2007-02-20|Carboxylic acid derivatives and drugs containing the same as the active ingredient

---

US4826868A|1989-05-02|1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use

---

DE60214428T2|2007-09-20|1, 4-dihydro-1, 4-diphenylpyridine derivatives

---

RU2128644C1|1999-04-10|Derivatives of anthranilic acid or their pharmacologically acceptable salts, intermediate compounds used for their synthesis and drug

---

EP2061762B1|2011-07-27|Pyrazine compounds, their use and methods of preparation

---

CA2565660C|2009-11-03|Ortho substituted aryl or heteroaryl amide compounds

---

JP4846978B2|2011-12-28|Oxindole hydrazine modulator of protein tyrosine phosphatase

---

ES2429570T3|2013-11-15|11-beta-hydroxysteroid dehydrogenase 1 inhibitors

---

US5283352A|1994-02-01|Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same

---

KR101478933B1|2015-01-02|Compositions and methods of treating cell proliferation disorders

---

DE3433327C2|1998-07-16|1-Heteroaryl-4 - [| alkyl] piperazine derivatives, process for their preparation and pharmaceutical compositions containing them

---

JP5189078B2|2013-04-24|Inhibitors of 11-β-hydroxysteroid dehydrogenase 1

---

KR860001818B1|1986-10-24|Process for the preparation of 2-amino-5-hydroxy-4-methylpyrimidine derivatives

同族专利:

---

公开号 | 公开日

---

CN1505603A|2004-06-16|

---

EP1437339A4|2006-10-04|

---

BR0206036A|2004-01-06|

---

CA2429005A1|2003-03-27|

---

US20040039061A1|2004-02-26|

---

US7122543B2|2006-10-17|

---

EP1437339A1|2004-07-14|

---

HU0303760A2|2004-03-01|

---

WO2003024913A1|2003-03-27|

---

JPWO2003024913A1|2004-12-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-09-17|Priority to JPJP-P-2001-00282255

---

2001-09-17|Priority to JP2001282255

---

2002-09-11|Application filed by 다이이찌 산토리 파마 가부시키가이샤, 가부시키가이샤 다이이찌 산토리 세이부쓰 이가쿠 겐큐쇼

---

2002-09-11|Priority to PCT/JP2002/009298

---

2004-04-28|Publication of KR20040034573A

优先权:

---

申请号 | 申请日 | 专利标题

---

JPJP-P-2001-00282255|2001-09-17|

---

JP2001282255|2001-09-17|

---

PCT/JP2002/009298|WO2003024913A1|2001-09-17|2002-09-11|SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY|